{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:43:31Z","timestamp":1793882611374,"version":"4.7.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016418","name":"B.K. Kee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019650","name":"Vir Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000290","name":"Children's Liver Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014386","name":"Abbott Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.cgh.2021.07.036","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T12:04:59Z","timestamp":1627387499000},"page":"1766-1775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update"],"prefix":"10.1016","volume":"20","author":[{"given":"Paul","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl T.-Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.07.036_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.30831","article-title":"Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999-2016","volume":"71","author":"Le","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.07.036_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.28109","article-title":"Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012","volume":"63","author":"Roberts","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41424-018-0007-6","article-title":"Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015","volume":"9","author":"Liu","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2021.07.036_bib6","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cgh.2010.11.040","article-title":"Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B","volume":"9","author":"Schiff","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.07.036_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib10","doi-asserted-by":"crossref","first-page":"e4433","DOI":"10.1097\/MD.0000000000004433","article-title":"Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis","volume":"95","author":"Hoang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.cgh.2021.07.036_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/apt.13774","article-title":"Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients","volume":"44","author":"Lin","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.07.036_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cgh.2018.10.012","article-title":"Poor adherence to guidelines for treatment of chronic hepatitis B virus infection at primary care and referral practices","volume":"17","author":"Nguyen","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/apt.14801","article-title":"Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience","volume":"48","author":"Chen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.07.036_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1844","article-title":"Diagnosis rates of chronic hepatitis B in privately insured patients in the United States","volume":"3","author":"Ogawa","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2021.07.036_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1440-1746.2009.06023.x","article-title":"Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population","volume":"25","author":"Jung","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2010.01401.x","article-title":"Is chronic hepatitis B being undertreated in the United States?","volume":"18","author":"Cohen","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2021.07.036_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13187-013-0466-0","article-title":"Prevalence, risk factors, and disease knowledge of chronic hepatitis B infection in Vietnamese Americans in California","volume":"28","author":"Ha","year":"2013","journal-title":"J\u00a0Cancer Educ"},{"issue":"Suppl 3","key":"10.1016\/j.cgh.2021.07.036_bib18","first-page":"S10","article-title":"Understanding cultural barriers in hepatitis B virus infection","volume":"76","author":"Tran","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.cgh.2021.07.036_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1542-3565(03)00312-4","article-title":"A\u00a0treatment algorithm for the management of chronic hepatitis B virus infection in the United States","volume":"2","author":"Keeffe","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.cgh.2006.05.016","article-title":"A\u00a0treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update","volume":"4","author":"Keeffe","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A\u00a0treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update","volume":"6","author":"Keeffe","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib22","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.cgh.2015.07.007","article-title":"A\u00a0treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update","volume":"13","author":"Martin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.07.036_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib25","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.12370","article-title":"Treating immune-tolerant hepatitis B","volume":"22","author":"Tseng","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2021.07.036_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/v9050096","article-title":"Immune tolerant chronic hepatitis B: the unrecognized risks","volume":"9","author":"Kennedy","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.cgh.2021.07.036_bib28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/JCM.41.3.1277-1279.2003","article-title":"Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients","volume":"41","author":"Chan","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cgh.2021.07.036_bib29","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1053\/j.gastro.2007.08.039","article-title":"Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"133","author":"Chu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.07.036_bib30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.07.036_bib31","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cgh.2021.07.036_bib32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.07.036_bib33","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase","author":"Huang","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.07.036_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7150\/ijms.5472","article-title":"Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-na\u00efve chronic hepatitis B patients in real life","volume":"10","author":"Luo","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cgh.2021.07.036_bib36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment","volume":"29","author":"Seto","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib37","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2021.07.036_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","author":"Babusis","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cgh.2021.07.036_bib39","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2021.07.036_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J\u00a0Acquir Immune Def Syndr"},{"key":"10.1016\/j.cgh.2021.07.036_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.31793","article-title":"Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice","volume":"74","author":"Toyoda","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib46","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","article-title":"Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir","volume":"116","author":"Nguyen","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.07.036_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Study 149 Investigators. Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.07.036_bib48","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib49","first-page":"446","article-title":"Extended treatment with peginterferon \u03b1-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion","volume":"14","author":"Cao","year":"2013","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cgh.2021.07.036_bib50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96 weeks peginterferon \u03b1-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"Lampertico","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.07.036_bib51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib52","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib54","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.07.036_bib56","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MCG.0b013e31825ceed9","article-title":"High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy","volume":"46","author":"Chaung","year":"2012","journal-title":"J\u00a0Clinical Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.07.036_bib57","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(17)30314-8","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: a prospective Greek study","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib58","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.07.036_bib59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/liv.13314","article-title":"When can we stop nucleoside analogues in patients with chronic hepatitis B?","volume":"37","author":"Chong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.07.036_bib60","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"Berg","year":"2017","journal-title":"J\u00a0Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2015.05.002","article-title":"Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?","volume":"68","author":"Buti","year":"2015","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cgh.2021.07.036_bib63","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","article-title":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil","volume":"50","author":"Ha","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib64","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"The aging kidney: physiological changes","volume":"17","author":"Weinstein","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.cgh.2021.07.036_bib65","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/hep.30246","article-title":"Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B","volume":"69","author":"Nguyen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib66","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/hep.30833","article-title":"an aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000 to 2017","volume":"71","author":"Wong","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/apt.15867","article-title":"Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B","volume":"52","author":"Oh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.07.036_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000511585","article-title":"Increasing age and nonliver comorbidities in patients with chronic hepatitis B in Taiwan: a nationwide population-based analysis","volume":"39","author":"Tseng","year":"2021","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2021.07.036_bib69","article-title":"Characteristics and healthcare costs in the aging hepatitis B population of Japan: a nationwide real-world analysis","author":"Yotsuyanagi","year":"2021","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2021.07.036_bib70","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ki.2014.363","article-title":"A\u00a0nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan","volume":"87","author":"Chen","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.cgh.2021.07.036_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12882-015-0106-5","article-title":"13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan","volume":"16","author":"Chen","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cgh.2021.07.036_bib72","first-page":"1178","article-title":"Association between exposure to hepatitis B virus and chronic kidney disease in China","volume":"42","author":"Zeng","year":"2014","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.cgh.2021.07.036_bib73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.07.036_bib74","article-title":"Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cgh.2021.07.036_bib75","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.07.036_bib76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2213-8587(21)00020-6","article-title":"Chronic hepatitis, osteoporosis, and men: under-recognised and underdiagnosed","volume":"9","author":"Prasad","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cgh.2021.07.036_bib77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib78","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.26910","article-title":"Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib79","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"VIRGIL Surveillance Study Group. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of na\u00efve patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib80","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jvh.12368","article-title":"Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir","volume":"22","author":"Lu","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2021.07.036_bib81","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCG.0b013e318266fd31","article-title":"Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily","volume":"47","author":"Ha","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2021.07.036_bib82","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib83","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s10620-011-1610-5","article-title":"Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"56","author":"Ha","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2021.07.036_bib84","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"Hongthanakorn","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/hep4.1022","article-title":"Resistance mutations of hepatitis B virus in entecavir-refractory patients","volume":"1","author":"Yamada","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2021.07.036_bib86","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: Update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.036_bib87","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib88","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2021.07.036_bib89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3350\/cmh.2013.19.3.195","article-title":"Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade","volume":"19","author":"Yim","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.036_bib90","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17512433.2019.1567327","article-title":"Novel developments of hepatitis B: treatment goals, agents and monitoring tools","volume":"12","author":"Mak","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cgh.2021.07.036_bib91","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl S1","key":"10.1016\/j.cgh.2021.07.036_bib92","first-page":"490A","article-title":"Maintenance of high levels of viral suppression and improved safety profile of tenofovir alafenamide (TAF) relative to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients treated for 5 years in 2 ongoing Phase 3 studies","volume":"72","author":"Chan","year":"2020","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521008181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521008181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:40:26Z","timestamp":1761543626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521008181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1542356521008181"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.07.036","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}